Servier shared a post on LinkedIn:
“ESMOGI26 is now over! We were pleased to engage with the global oncology community, share perspectives, and exchange on the latest advances in gastrointestinal oncology.
For the past 10 years, oncology has been a major therapeutic priority for us, accounting for close to 70% of our R&D investment. In May 2026, our oncology pipeline comprised 38 projects, 23 of which in clinical development and 15 research projects.
Learn more about our commitment in oncology.
Thank you to everyone who engaged with us during the congress – see you soon!”
Other articles about Servier on OncoDaily.